Schoepfer J - Search Results

1

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pellé X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P. Schoepfer J, et al. J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7. J Med Chem. 2018. PMID: 30137981

2

Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.

Furet P, Gay B, García-Echeverría C, Rahuel J, Fretz H, Schoepfer J, Caravatti G. Furet P, et al. Among authors: schoepfer j. J Med Chem. 1997 Oct 24;40(22):3551-6. doi: 10.1021/jm9702185. J Med Chem. 1997. PMID: 9357522

3

Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2.

García-Echeverría C, Furet P, Gay B, Fretz H, Rahuel J, Schoepfer J, Caravatti G. García-Echeverría C, et al. Among authors: schoepfer j. J Med Chem. 1998 May 21;41(11):1741-4. doi: 10.1021/jm970856n. J Med Chem. 1998. PMID: 9599224 No abstract available.

4

Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.

Rahuel J, García-Echeverría C, Furet P, Strauss A, Caravatti G, Fretz H, Schoepfer J, Gay B. Rahuel J, et al. Among authors: schoepfer j. J Mol Biol. 1998 Jun 19;279(4):1013-22. doi: 10.1006/jmbi.1998.1790. J Mol Biol. 1998. PMID: 9642078

5

Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.

Furet P, Gay B, Caravatti G, García-Echeverría C, Rahuel J, Schoepfer J, Fretz H. Furet P, et al. Among authors: schoepfer j. J Med Chem. 1998 Aug 27;41(18):3442-9. doi: 10.1021/jm980159a. J Med Chem. 1998. PMID: 9719597

6

Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.

Schoepfer J, Gay B, Caravatti G, Garcia-Echeverria C, Fretz H, Rahuel J, Furet P. Schoepfer J, et al. Bioorg Med Chem Lett. 1998 Oct 20;8(20):2865-70. doi: 10.1016/s0960-894x(98)00513-7. Bioorg Med Chem Lett. 1998. PMID: 9873638

7

Highly potent inhibitors of the Grb2-SH2 domain.

Schoepfer J, Fretz H, Gay B, Furet P, García-Echeverría C, End N, Caravatti G. Schoepfer J, et al. Bioorg Med Chem Lett. 1999 Jan 18;9(2):221-6. doi: 10.1016/s0960-894x(98)00701-x. Bioorg Med Chem Lett. 1999. PMID: 10021933

8

Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.

Furet P, García-Echeverría C, Gay B, Schoepfer J, Zeller M, Rahuel J. Furet P, et al. Among authors: schoepfer j. J Med Chem. 1999 Jul 1;42(13):2358-63. doi: 10.1021/jm991013u. J Med Chem. 1999. PMID: 10395476

9

Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility.

Gay B, Suarez S, Weber C, Rahuel J, Fabbro D, Furet P, Caravatti G, Schoepfer J. Gay B, et al. Among authors: schoepfer j. J Biol Chem. 1999 Aug 13;274(33):23311-5. doi: 10.1074/jbc.274.33.23311. J Biol Chem. 1999. PMID: 10438507 Free article.

10

Selective GRB2 SH2 inhibitors as anti-Ras therapy.

Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Gay B, et al. Among authors: schoepfer j. Int J Cancer. 1999 Oct 8;83(2):235-41. doi: 10.1002/(sici)1097-0215(19991008)83:2<235::aid-ijc15>3.0.co;2-b. Int J Cancer. 1999. PMID: 10471533 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page